{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:27:39Z","timestamp":1792664859441,"version":"4.5.0"},"reference-count":149,"publisher":"Japan Endocrine Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1507\/endocrj.ej25-0087","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T22:06:28Z","timestamp":1743631588000},"page":"751-764","source":"Crossref","is-referenced-by-count":15,"title":["Physiology and clinical applications of GIP"],"prefix":"10.1507","volume":"72","author":[{"given":"Shunsuke","family":"Yamane","sequence":"first","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8720-1013","authenticated-orcid":false,"given":"Norio","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan"},{"name":"Department of Endocrinology and Metabolism, School of Medical Sciences, University of Fukui, Fukui 910-1193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8261-2593","authenticated-orcid":false,"given":"Nobuya","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan"},{"name":"Medical Research Institute KITANO HOSPITAL, P.I.I.F. Tazuke-Kofukai, Osaka 530-8480, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Seino Y, Yabe D (2013) Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Investig 4: 108\u2013130.","DOI":"10.1111\/jdi.12065"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2 Drucker DJ (1998) Glucagon-like peptides. Diabetes 47: 159\u2013169.","DOI":"10.2337\/diabetes.47.2.159"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Krarup T, Holst JJ, Larsen KL (1985) Responses and molecular heterogeneity of IR-GIP after intraduodenal glucose and fat. Am J Physiol 249: E195\u2013E200.","DOI":"10.1152\/ajpendo.1985.249.2.E195"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Brown JC, Mutt V, Pederson RA (1970) Further purification of a polypeptide demonstrating enterogastrone activity. J Physiol 209: 57\u201364.","DOI":"10.1113\/jphysiol.1970.sp009155"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Dupre J, Ross SA, Watson D, Brown JC (1973) Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 37: 826\u2013828.","DOI":"10.1210\/jcem-37-5-826"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Andersen DK, Elahi D, Brown JC, Tobin JD, Andres R (1978) Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels. J Clin Invest 62: 152\u2013161.","DOI":"10.1172\/JCI109100"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Takeda J, Seino Y, Tanaka K, Fukumoto H, Kayano T, et al. (1987) Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor. Proc Natl Acad Sci U S A 84: 7005\u20137008.","DOI":"10.1073\/pnas.84.20.7005"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Inagaki N, Seino Y, Takeda J, Yano H, Yamada Y, et al. (1989) Gastric inhibitory polypeptide: structure and chromosomal localization of the human gene. Mol Endocrinol 3: 1014\u20131021.","DOI":"10.1210\/mend-3-6-1014"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Nauck M, Schmidt WE, Ebert R, Strietzel J, Cantor P, et al. (1989) Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. J Clin Endocrinol Metab 69: 654\u2013662.","DOI":"10.1210\/jcem-69-3-654"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Beumer J, Artegiani B, Post Y, Reimann F, Gribble F, et al. (2018) Enteroendocrine cells switch hormone expression along the crypt-to-villus BMP signalling gradient. Nat Cell Biol 20: 909\u2013916.","DOI":"10.1038\/s41556-018-0143-y"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Hatoko T, Harada N, Tokumoto S, Yamane S, Ikeguchi-Ogura E, et al. (2022) An analysis of intestinal morphology and incretin-producing cells using tissue optical clearing and 3-D imaging. Sci Rep 12: 17530.","DOI":"10.1038\/s41598-022-22511-7"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Kieffer TJ, McIntosh CH, Pederson RA (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 <i>in vitro<\/i> and <i>in vivo<\/i> by dipeptidyl peptidase IV. Endocrinology 136: 3585\u20133596.","DOI":"10.1210\/endo.136.8.7628397"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Yasuda K, Inagaki N, Yamada Y, Kubota A, Seino S, et al. (1994) Hamster gastric inhibitory polypeptide receptor expressed in pancreatic islets and clonal insulin-secreting cells: its structure and functional properties. Biochem Biophys Res Commun 205: 1556\u20131562.","DOI":"10.1006\/bbrc.1994.2844"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14 Yamada Y, Hayami T, Nakamura K, Kaisaki PJ, Someya Y, et al. (1995) Human gastric inhibitory polypeptide receptor: cloning of the gene (GIPR) and cDNA. Genomics 29: 773\u2013776.","DOI":"10.1006\/geno.1995.9937"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Gremlich S, Porret A, Hani EH, Cherif D, Vionnet N, et al. (1995) Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor. Diabetes 44: 1202\u20131208.","DOI":"10.2337\/diabetes.44.10.1202"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Seino Y, Fukushima M, Yabe D (2010) GIP and GLP-1, the two incretin hormones: Similarities and differences. J Diabetes Investig 1: 8\u201323.","DOI":"10.1111\/j.2040-1124.2010.00022.x"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17 Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI (1993) Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 133: 2861\u20132870.","DOI":"10.1210\/endo.133.6.8243312"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Tsukiyama K, Yamada Y, Yamada C, Harada N, Kawasaki Y, et al. (2006) Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Mol Endocrinol 20: 1644\u20131651.","DOI":"10.1210\/me.2005-0187"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Ogawa E, Hosokawa M, Harada N, Yamane S, Hamasaki A, et al. (2011) The effect of gastric inhibitory polypeptide on intestinal glucose absorption and intestinal motility in mice. Biochem Biophys Res Commun 404: 115\u2013120.","DOI":"10.1016\/j.bbrc.2010.11.077"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Yamada Y, Tsukiyama K, Sato T, Shimizu T, Fujita H, et al. (2016) Novel extrapancreatic effects of incretin. J Diabetes Investig 7 Suppl 1: 76\u201379.","DOI":"10.1111\/jdi.12495"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21 Himeno T, Kamiya H, Naruse K, Harada N, Ozaki N, et al. (2011) Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice. Diabetes 60: 2397\u20132406.","DOI":"10.2337\/db10-1462"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Habib AM, Richards P, Cairns LS, Rogers GJ, Bannon CA, et al. (2012) Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. Endocrinology 153: 3054\u20133065.","DOI":"10.1210\/en.2011-2170"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Gehart H, van Es JH, Hamer K, Beumer J, Kretzschmar K, et al. (2019) Identification of enteroendocrine regulators by real-time single-cell differentiation mapping. Cell 176: 1158\u20131173.e1116.","DOI":"10.1016\/j.cell.2018.12.029"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Fothergill LJ, Furness JB (2018) Diversity of enteroendocrine cells investigated at cellular and subcellular levels: the need for a new classification scheme. Histochem Cell Biol 150: 693\u2013702.","DOI":"10.1007\/s00418-018-1746-x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Hysenaj F, Lauber M, Bast-Habersbrunner A, List M, Klingenspor M (2024) Single-cell transcriptome analysis reveals secretin as a hallmark of human enteroendocrine cell maturation. Sci Rep 14: 13525.","DOI":"10.1038\/s41598-024-63699-0"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Morgan LM, Morris BA, Marks V (1978) Radioimmunoassay of gastric inhibitory polypeptide. Ann Clin Biochem 15: 172\u2013177.","DOI":"10.1177\/000456327801500138"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Kay RG, Foreman RE, Roberts GP, Hardwick R, Reimann F, et al. (2020) Mass spectrometric characterisation of the circulating peptidome following oral glucose ingestion in control and gastrectomised patients. Rapid Commun Mass Spectrom 34: e8849.","DOI":"10.1002\/rcm.8849"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Reimann F, Diakogiannaki E, Hodge D, Gribble FM (2020) Cellular mechanisms governing glucose-dependent insulinotropic polypeptide secretion. Peptides 125: 170206.","DOI":"10.1016\/j.peptides.2019.170206"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Guccio N, Gribble FM, Reimann F (2022) Glucose-dependent insulinotropic polypeptide-a postprandial hormone with unharnessed metabolic potential. Annu Rev Nutr 42: 21\u201344.","DOI":"10.1146\/annurev-nutr-062320-113625"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Cataland S, Crockett SE, Brown JC, Mazzaferri EL (1974) Gastric inhibitory polypeptide (GIP) stimulation by oral glucose in man. J Clin Endocrinol Metab 39: 223\u2013228.","DOI":"10.1210\/jcem-39-2-223"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31 Parker HE, Habib AM, Rogers GJ, Gribble FM, Reimann F (2009) Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 52: 289\u2013298.","DOI":"10.1007\/s00125-008-1202-x"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Sykes S, Morgan LM, English J, Marks V (1980) Evidence for preferential stimulation of gastric inhibitory polypeptide secretion in the rat by actively transported carbohydrates and their analogues. J Endocrinol 85: 201\u2013207.","DOI":"10.1677\/joe.0.0850201"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, et al. (2008) Glucose sensing in L cells: a primary cell study. Cell Metab 8: 532\u2013539.","DOI":"10.1016\/j.cmet.2008.11.002"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Kuhre RE, Frost CR, Svendsen B, Holst JJ (2015) Molecular mechanisms of glucose-stimulated GLP-1 secretion from perfused rat small intestine. Diabetes 64: 370\u2013382.","DOI":"10.2337\/db14-0807"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Sun EW, de Fontgalland D, Rabbitt P, Hollington P, Sposato L, et al. (2017) Mechanisms controlling glucose-induced GLP-1 secretion in human small intestine. Diabetes 66: 2144\u20132149.","DOI":"10.2337\/db17-0058"},{"key":"36","doi-asserted-by":"publisher","unstructured":"36 Gorboulev V, Sch\u00fcrmann A, Vallon V, Kipp H, Jaschke A, et al. (2012) Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61: 187\u2013196.","DOI":"10.2337\/db11-1029"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 He YL, Haynes W, Meyers CD, Amer A, Zhang Y, et al. (2019) The effects of licogliflozin, a dual SGLT1\/2 inhibitor, on body weight in obese patients with or without diabetes. Diabetes Obes Metab 21: 1311\u20131321.","DOI":"10.1111\/dom.13654"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Uldry M, Thorens B (2004) The SLC2 family of facilitated hexose and polyol transporters. Pflugers Arch 447: 480\u2013489.","DOI":"10.1007\/s00424-003-1085-0"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Kuhre RE, Gribble FM, Hartmann B, Reimann F, Windel\u00f8v JA, et al. (2014) Fructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans. Am J Physiol Gastrointest Liver Physiol 306: G622\u2013G630.","DOI":"10.1152\/ajpgi.00372.2013"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Seino Y, Maekawa R, Ogata H, Hayashi Y (2016) Carbohydrate-induced secretion of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. J Diabetes Investig 7 Suppl 1: 27\u201332.","DOI":"10.1111\/jdi.12449"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Flatt PR, Kwasowski P, Bailey CJ (1989) Stimulation of gastric inhibitory polypeptide release in ob\/ob mice by oral administration of sugars and their analogues. J Nutr 119: 1300\u20131303.","DOI":"10.1093\/jn\/119.9.1300"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Ogata H, Seino Y, Harada N, Iida A, Suzuki K, et al. (2014) KATP channel as well as SGLT1 participates in GIP secretion in the diabetic state. J Endocrinol 222: 191\u2013200.","DOI":"10.1530\/JOE-14-0161"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Stephens JW, Bodvarsdottir TB, Wareham K, Prior SL, Bracken RM, et al. (2011) Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus. Diabetes Res Clin Pract 94: 199\u2013206.","DOI":"10.1016\/j.diabres.2011.07.014"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Margolskee RF, Dyer J, Kokrashvili Z, Salmon KS, Ilegems E, et al. (2007) T1R3 and gustducin in gut sense sugars to regulate expression of Na+-glucose cotransporter 1. Proc Natl Acad Sci U S A 104: 15075\u201315080.","DOI":"10.1073\/pnas.0706678104"},{"key":"45","doi-asserted-by":"publisher","unstructured":"45 Saltiel MY, Kuhre RE, Christiansen CB, Eliasen R, Conde-Frieboes KW, et al. (2017) Sweet taste receptor activation in the gut is of limited importance for glucose-stimulated GLP-1 and GIP secretion. Nutrients 9: 418.","DOI":"10.3390\/nu9040418"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Fujita Y, Wideman RD, Speck M, Asadi A, King DS, et al. (2009) Incretin release from gut is acutely enhanced by sugar but not by sweeteners <i>in vivo<\/i>. Am J Physiol Endocrinol Metab 296: E473\u2013E479.","DOI":"10.1152\/ajpendo.90636.2008"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Wu T, Zhao BR, Bound MJ, Checklin HL, Bellon M, et al. (2012) Effects of different sweet preloads on incretin hormone secretion, gastric emptying, and postprandial glycemia in healthy humans. Am J Clin Nutr 95: 78\u201383.","DOI":"10.3945\/ajcn.111.021543"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Kreuch D, Keating DJ, Wu T, Horowitz M, Rayner CK, et al. (2018) Gut mechanisms linking intestinal sweet sensing to glycemic control. Front Endocrinol (Lausanne) 9: 741.","DOI":"10.3389\/fendo.2018.00741"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Yamane S, Harada N, Inagaki N (2016) Mechanisms of fat-induced gastric inhibitory polypeptide\/glucose-dependent insulinotropic polypeptide secretion from K cells. J Diabetes Investig 7 Suppl 1: 20\u201326.","DOI":"10.1111\/jdi.12467"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Yamane S, Harada N, Hamasaki A, Muraoka A, Joo E, et al. (2012) Effects of glucose and meal ingestion on incretin secretion in Japanese subjects with normal glucose tolerance. J Diabetes Investig 3: 80\u201385.","DOI":"10.1111\/j.2040-1124.2011.00143.x"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Wu T, Rayner CK, Watson LE, Jones KL, Horowitz M, et al. (2017) Comparative effects of intraduodenal fat and glucose on the gut-incretin axis in healthy males. Peptides 95: 124\u2013127.","DOI":"10.1016\/j.peptides.2017.08.001"},{"key":"52","doi-asserted-by":"publisher","unstructured":"52 Edfalk S, Steneberg P, Edlund H (2008) Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 57: 2280\u20132287.","DOI":"10.2337\/db08-0307"},{"key":"53","doi-asserted-by":"publisher","unstructured":"53 Iwasaki K, Harada N, Sasaki K, Yamane S, Iida K, et al. (2015) Free fatty acid receptor GPR120 is highly expressed in enteroendocrine K cells of the upper small intestine and has a critical role in GIP secretion after fat ingestion. Endocrinology 156: 837\u2013846.","DOI":"10.1210\/en.2014-1653"},{"key":"54","doi-asserted-by":"publisher","unstructured":"54 Sankoda A, Harada N, Iwasaki K, Yamane S, Murata Y, et al. (2017) Long-chain free fatty acid receptor GPR120 mediates oil-induced GIP secretion through CCK in male mice. Endocrinology 158: 1172\u20131180.","DOI":"10.1210\/en.2017-00090"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55 Ekberg JH, Hauge M, Kristensen LV, Madsen AN, Engelstoft MS, et al. (2016) GPR119, a major enteroendocrine sensor of dietary triglyceride metabolites coacting in synergy with FFA1 (GPR40). Endocrinology 157: 4561\u20134569.","DOI":"10.1210\/en.2016-1334"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Sankoda A, Harada N, Kato T, Ikeguchi E, Iwasaki K, et al. (2019) Free fatty acid receptors, G protein-coupled receptor 120 and G protein-coupled receptor 40, are essential for oil-induced gastric inhibitory polypeptide secretion. J Diabetes Investig 10: 1430\u20131437.","DOI":"10.1111\/jdi.13059"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57 Yasuda T, Harada N, Hatoko T, Ichimura A, Ikeguchi-Ogura E, et al. (2023) Inhibition of GPR120 signaling in intestine ameliorates insulin resistance and fatty liver under high-fat diet feeding. Am J Physiol Endocrinol Metab 324: E449\u2013E460.","DOI":"10.1152\/ajpendo.00329.2022"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58 Murata Y, Harada N, Kishino S, Iwasaki K, Ikeguchi-Ogura E, et al. (2021) Medium-chain triglycerides inhibit long-chain triglyceride-induced GIP secretion through GPR120-dependent inhibition of CCK. iScience 24: 102963.","DOI":"10.1016\/j.isci.2021.102963"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59 Murata Y, Harada N, Yamane S, Iwasaki K, Ikeguchi E, et al. (2019) Medium-chain triglyceride diet stimulates less GIP secretion and suppresses body weight and fat mass gain compared with long-chain triglyceride diet. Am J Physiol Endocrinol Metab 317: E53\u2013E64.","DOI":"10.1152\/ajpendo.00200.2018"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60 Hansen KB, Rosenkilde MM, Knop FK, Wellner N, Diep TA, et al. (2011) 2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans. J Clin Endocrinol Metab 96: E1409\u2013E1417.","DOI":"10.1210\/jc.2011-0647"},{"key":"61","doi-asserted-by":"publisher","unstructured":"61 Chu ZL, Carroll C, Alfonso J, Gutierrez V, He H, et al. (2008) A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release. Endocrinology 149: 2038\u20132047.","DOI":"10.1210\/en.2007-0966"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62 Kuhre RE, Wewer Albrechtsen NJ, Larsen O, Jepsen SL, Balk-M\u00f8ller E, et al. (2018) Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas. Mol Metab 11: 84\u201395.","DOI":"10.1016\/j.molmet.2018.03.007"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63 McGlone ER, Malallah K, Cuenco J, Wewer Albrechtsen NJ, Holst JJ, et al. (2021) Differential effects of bile acids on the postprandial secretion of gut hormones: a randomized crossover study. Am J Physiol Endocrinol Metab 320: E671\u2013E679.","DOI":"10.1152\/ajpendo.00580.2020"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64 Shibue K, Yamane S, Harada N, Hamasaki A, Suzuki K, et al. (2015) Fatty acid-binding protein 5 regulates diet-induced obesity <i>via<\/i> GIP secretion from enteroendocrine K cells in response to fat ingestion. Am J Physiol Endocrinol Metab 308: E583\u2013E591.","DOI":"10.1152\/ajpendo.00543.2014"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65 Okawa M, Fujii K, Ohbuchi K, Okumoto M, Aragane K, et al. (2009) Role of MGAT2 and DGAT1 in the release of gut peptides after triglyceride ingestion. Biochem Biophys Res Commun 390: 377\u2013381.","DOI":"10.1016\/j.bbrc.2009.08.167"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66 Sommer CA, Mostoslavsky G (2014) RNA-Seq analysis of enteroendocrine cells reveals a role for FABP5 in the control of GIP secretion. Mol Endocrinol 28: 1855\u20131865.","DOI":"10.1210\/me.2014-1194"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67 Fujita Y, Chui JW, King DS, Zhang T, Seufert J, et al. (2008) Pax6 and Pdx1 are required for production of glucose-dependent insulinotropic polypeptide in proglucagon-expressing L cells. Am J Physiol Endocrinol Metab 295: E648\u2013E657.","DOI":"10.1152\/ajpendo.90440.2008"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68 Suzuki K, Harada N, Yamane S, Nakamura Y, Sasaki K, et al. (2013) Transcriptional regulatory factor X6 (Rfx6) increases gastric inhibitory polypeptide (GIP) expression in enteroendocrine K-cells and is involved in GIP hypersecretion in high fat diet-induced obesity. J Biol Chem 288: 1929\u20131938.","DOI":"10.1074\/jbc.M112.423137"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69 Patel KA, Kettunen J, Laakso M, Stan\u010d\u00e1kov\u00e1 A, Laver TW, et al. (2017) Heterozygous RFX6 protein truncating variants are associated with MODY with reduced penetrance. Nat Commun 8: 888.","DOI":"10.1038\/s41467-017-00895-9"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70 Gniuli D, Calcagno A, Dalla Libera L, Calvani R, Leccesi L, et al. (2010) High-fat feeding stimulates endocrine, glucose-dependent insulinotropic polypeptide (GIP)-expressing cell hyperplasia in the duodenum of Wistar rats. Diabetologia 53: 2233\u20132240.","DOI":"10.1007\/s00125-010-1830-9"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71 Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, et al. (1993) Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 138: 159\u2013166.","DOI":"10.1677\/joe.0.1380159"},{"key":"72","doi-asserted-by":"publisher","unstructured":"72 Thomas FB, Mazzaferri EL, Crockett SE, Mekhjian HS, Gruemer HD, et al. (1976) Stimulation of secretion of gastric inhibitory polypeptide and insulin by intraduodenal amino acid perfusion. Gastroenterology 70: 523\u2013527.","DOI":"10.1016\/S0016-5085(76)80489-1"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73 Mace OJ, Schindler M, Patel S (2012) The regulation of K- and L-cell activity by GLUT2 and the calcium-sensing receptor CasR in rat small intestine. J Physiol 590: 2917\u20132936.","DOI":"10.1113\/jphysiol.2011.223800"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74 Feng J, Kang C, Wang C, Ding L, Zhu W, et al. (2019) L-phenylalanine increased gut hormone secretion through calcium-sensing receptor in the porcine duodenum. Animals (Basel) 9: 476.","DOI":"10.3390\/ani9080476"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75 Zhao X, Xian Y, Wang C, Ding L, Meng X, et al. (2018) Calcium-sensing receptor-mediated L-tryptophan-induced secretion of cholecystokinin and glucose-dependent insulinotropic peptide in swine duodenum. J Vet Sci 19: 179\u2013187.","DOI":"10.4142\/jvs.2018.19.2.179"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76 Wang C, Kang C, Xian Y, Zhang M, Chen X, et al. (2018) Sensing of L-arginine by gut-expressed calcium sensing receptor stimulates gut satiety hormones cholecystokinin and glucose-dependent insulinotropic peptide secretion in pig model. J Food Sci 83: 2394\u20132401.","DOI":"10.1111\/1750-3841.14297"},{"key":"77","doi-asserted-by":"publisher","unstructured":"77 Inagaki N, Gonoi T, Clement JPt, Namba N, Inazawa J, et al. (1995) Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science 270: 1166\u20131170.","DOI":"10.1126\/science.270.5239.1166"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78 Seino S, Shibasaki T, Minami K (2011) Dynamics of insulin secretion and the clinical implications for obesity and diabetes. J Clin Invest 121: 2118\u20132125.","DOI":"10.1172\/JCI45680"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79 Rutter GA (2004) Visualising insulin secretion. The Minkowski lecture 2004. Diabetologia 47: 1861\u20131872.","DOI":"10.1007\/s00125-004-1541-1"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80 Rutter GA, Pullen TJ, Hodson DJ, Martinez-Sanchez A (2015) Pancreatic \u03b2-cell identity, glucose sensing and the control of insulin secretion. Biochem J 466: 203\u2013218.","DOI":"10.1042\/BJ20141384"},{"key":"81","doi-asserted-by":"publisher","unstructured":"81 Ding WG, Gromada J (1997) Protein kinase A-dependent stimulation of exocytosis in mouse pancreatic beta-cells by glucose-dependent insulinotropic polypeptide. Diabetes 46: 615\u2013621.","DOI":"10.2337\/diabetes.46.4.615"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82 Skelin M, Rupnik M (2011) cAMP increases the sensitivity of exocytosis to Ca<sup>2+<\/sup> primarily through protein kinase A in mouse pancreatic beta cells. Cell Calcium 49: 89\u201399.","DOI":"10.1016\/j.ceca.2010.12.005"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83 Shibasaki T, Takahashi H, Miki T, Sunaga Y, Matsumura K, et al. (2007) Essential role of Epac2\/Rap1 signaling in regulation of insulin granule dynamics by cAMP. Proc Natl Acad Sci U S A 104: 19333\u201319338.","DOI":"10.1073\/pnas.0707054104"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84 Harada N, Inagaki N (2017) Role of GIP receptor signaling in \u03b2-cell survival. Diabetol Int 8: 137\u2013138.","DOI":"10.1007\/s13340-017-0317-z"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85 Kim SJ, Nian C, Widenmaier S, McIntosh CH (2008) Glucose-dependent insulinotropic polypeptide-mediated up-regulation of beta-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2. Mol Cell Biol 28: 1644\u20131656.","DOI":"10.1128\/MCB.00325-07"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86 Kim SJ, Winter K, Nian C, Tsuneoka M, Koda Y, et al. (2005) Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)\/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression. J Biol Chem 280: 22297\u201322307.","DOI":"10.1074\/jbc.M500540200"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87 Ehses JA, Pelech SL, Pederson RA, McIntosh CH (2002) Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1\/2-ERK1\/2 module <i>via<\/i> a cyclic AMP\/cAMP-dependent protein kinase\/Rap1-mediated pathway. J Biol Chem 277: 37088\u201337097.","DOI":"10.1074\/jbc.M205055200"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88 Friedrichsen BN, Neubauer N, Lee YC, Gram VK, Blume N, et al. (2006) Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 <i>via<\/i> multiple signalling pathways. J Endocrinol 188: 481\u2013492.","DOI":"10.1677\/joe.1.06160"},{"key":"89","doi-asserted-by":"publisher","unstructured":"89 Moens K, Heimberg H, Flamez D, Huypens P, Quartier E, et al. (1996) Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 45: 257\u2013261.","DOI":"10.2337\/diabetes.45.2.257"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90 Segerstolpe \u00c5, Palasantza A, Eliasson P, Andersson EM, Andr\u00e9asson AC, et al. (2016) Single-cell transcriptome profiling of human pancreatic islets in health and type 2 diabetes. Cell Metab 24: 593\u2013607.","DOI":"10.1016\/j.cmet.2016.08.020"},{"key":"91","doi-asserted-by":"publisher","unstructured":"91 Chia CW, Carlson OD, Kim W, Shin YK, Charles CP, et al. (2009) Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes 58: 1342\u20131349.","DOI":"10.2337\/db08-0958"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92 Opara EC, Go VL (1991) Influence of gastric inhibitory polypeptide (GIP) and glucose on the regulation of glucagon secretion by pancreatic alpha cells. Regul Pept 32: 65\u201373.","DOI":"10.1016\/0167-0115(91)90035-F"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93 Sparre-Ulrich AH, Gabe MN, Gasbjerg LS, Christiansen CB, Svendsen B, et al. (2017) GIP(3-30)NH(2) is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release. Biochem Pharmacol 131: 78\u201388.","DOI":"10.1016\/j.bcp.2017.02.012"},{"key":"94","doi-asserted-by":"publisher","unstructured":"94 Christensen M, Vedtofte L, Holst JJ, Vilsb\u00f8ll T, Knop FK (2011) Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 60: 3103\u20133109.","DOI":"10.2337\/db11-0979"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95 El K, Gray SM, Capozzi ME, Knuth ER, Jin E, et al. (2021) GIP mediates the incretin effect and glucose tolerance by dual actions on \u03b1 cells and \u03b2 cells. Sci Adv 7: eabf1948.","DOI":"10.1126\/sciadv.abf1948"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96 Harada N, Hamasaki A, Yamane S, Muraoka A, Joo E, et al. (2011) Plasma gastric inhibitory polypeptide and glucagon-like peptide-1 levels after glucose loading are associated with different factors in Japanese subjects. J Diabetes Investig 2: 193\u2013199.","DOI":"10.1111\/j.2040-1124.2010.00078.x"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97 Maekawa R, Ogata H, Murase M, Harada N, Suzuki K, et al. (2018) Glucose-dependent insulinotropic polypeptide is required for moderate high-fat diet- but not high-carbohydrate diet-induced weight gain. Am J Physiol Endocrinol Metab 314: E572\u2013E583.","DOI":"10.1152\/ajpendo.00352.2017"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98 Harada N, Yamada Y, Tsukiyama K, Yamada C, Nakamura Y, et al. (2008) A novel GIP receptor splice variant influences GIP sensitivity of pancreatic beta-cells in obese mice. Am J Physiol Endocrinol Metab 294: E61\u2013E68.","DOI":"10.1152\/ajpendo.00358.2007"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99 Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, et al. (2002) Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8: 738\u2013742.","DOI":"10.1038\/nm727"},{"key":"100","doi-asserted-by":"publisher","unstructured":"100 Nasteska D, Harada N, Suzuki K, Yamane S, Hamasaki A, et al. (2014) Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions. Diabetes 63: 2332\u20132343.","DOI":"10.2337\/db13-1563"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101 Boylan MO, Glazebrook PA, Tatalovic M, Wolfe MM (2015) Gastric inhibitory polypeptide immunoneutralization attenuates development of obesity in mice. Am J Physiol Endocrinol Metab 309: E1008\u2013E1018.","DOI":"10.1152\/ajpendo.00345.2015"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102 Kim SJ, Nian C, McIntosh CH (2010) GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene. J Lipid Res 51: 3145\u20133157.","DOI":"10.1194\/jlr.M006841"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103 Ugleholdt R, Pedersen J, Bassi MR, F\u00fcchtbauer EM, J\u00f8rgensen SM, et al. (2011) Transgenic rescue of adipocyte glucose-dependent insulinotropic polypeptide receptor expression restores high fat diet-induced body weight gain. J Biol Chem 286: 44632\u201344645.","DOI":"10.1074\/jbc.M111.311779"},{"key":"104","doi-asserted-by":"publisher","unstructured":"104 Joo E, Harada N, Yamane S, Fukushima T, Taura D, et al. (2017) Inhibition of gastric inhibitory polypeptide receptor signaling in adipose tissue reduces insulin resistance and hepatic steatosis in high-fat diet-fed mice. Diabetes 66: 868\u2013879.","DOI":"10.2337\/db16-0758"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105 Ikeguchi E, Harada N, Kanemaru Y, Sankoda A, Yamane S, et al. (2018) Transcriptional factor Pdx1 is involved in age-related GIP hypersecretion in mice. Am J Physiol Gastrointest Liver Physiol 315: G272\u2013G282.","DOI":"10.1152\/ajpgi.00054.2018"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106 Shimazu-Kuwahara S, Harada N, Yamane S, Joo E, Sankoda A, et al. (2017) Attenuated secretion of glucose-dependent insulinotropic polypeptide (GIP) does not alleviate hyperphagic obesity and insulin resistance in ob\/ob mice. Mol Metab 6: 288\u2013294.","DOI":"10.1016\/j.molmet.2017.01.006"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107 Shimazu-Kuwahara S, Kanemaru Y, Harada N, Ikeguchi E, Ueda Y, et al. (2019) Glucose-dependent insulinotropic polypeptide deficiency reduced fat accumulation and insulin resistance, but deteriorated bone loss in ovariectomized mice. J Diabetes Investig 10: 909\u2013914.","DOI":"10.1111\/jdi.12978"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108 Regmi A, Aihara E, Christe ME, Varga G, Beyer TP, et al. (2024) Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor. Cell Metab 36: 1534\u20131549.e1537.","DOI":"10.1016\/j.cmet.2024.05.010"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109 Yu X, Chen S, Funcke JB, Straub LG, Pirro V, et al. (2025) The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice. Cell Metab 37: 187\u2013204.e187.","DOI":"10.1016\/j.cmet.2024.11.003"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110 Zhang ZQ, H\u00f6lscher C (2020) GIP has neuroprotective effects in Alzheimer and Parkinson\u2019s disease models. Peptides 125: 170184.","DOI":"10.1016\/j.peptides.2019.170184"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111 Adriaenssens AE, Biggs EK, Darwish T, Tadross J, Sukthankar T, et al. (2019) Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake. Cell Metab 30: 987\u2013996.e986.","DOI":"10.1016\/j.cmet.2019.07.013"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112 Zhang Q, Delessa CT, Augustin R, Bakhti M, Colld\u00e9n G, et al. (2021) The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake <i>via<\/i> CNS-GIPR signaling. Cell Metab 33: 833\u2013844.e835.","DOI":"10.1016\/j.cmet.2021.01.015"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113 Kaneko K, Fu Y, Lin HY, Cordonier EL, Mo Q, et al. (2019) Gut\u2013derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition. J Clin Invest 129: 3786\u20133791.","DOI":"10.1172\/JCI126107"},{"key":"114","doi-asserted-by":"crossref","first-page":"e164921","DOI":"10.1172\/jci.insight.164921","volume":"8","author":"A Adriaenssens","year":"2023","unstructured":"114 Adriaenssens A, Broichhagen J, de Bray A, Ast J, Hasib A, et al. (2023) Hypothalamic and brainstem glucose-dependent insulinotropic polypeptide receptor neurons employ distinct mechanisms to affect feeding. JCI Insight 8: e164921.","journal-title":"JCI Insight","ISSN":"https:\/\/id.crossref.org\/issn\/2379-3708","issn-type":"print"},{"key":"115","doi-asserted-by":"crossref","unstructured":"115 Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, et al. (1993) Preserved incretin activity of glucagon-like peptide 1 [7\u201336 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91: 301\u2013307.","DOI":"10.1172\/JCI116186"},{"key":"116","doi-asserted-by":"crossref","unstructured":"116 H\u00f8jberg PV, Vilsb\u00f8ll T, Rab\u00f8l R, Knop FK, Bache M, et al. (2009) Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52: 199\u2013207.","DOI":"10.1007\/s00125-008-1195-5"},{"key":"117","doi-asserted-by":"crossref","unstructured":"117 Irwin N, Gault VA, O\u2019Harte FPM, Flatt PR (2020) Blockade of gastric inhibitory polypeptide (GIP) action as a novel means of countering insulin resistance in the treatment of obesity-diabetes. Peptides 125: 170203.","DOI":"10.1016\/j.peptides.2019.170203"},{"key":"118","doi-asserted-by":"crossref","unstructured":"118 McClean PL, Irwin N, Cassidy RS, Holst JJ, Gault VA, et al. (2007) GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am J Physiol Endocrinol Metab 293: E1746\u2013E1755.","DOI":"10.1152\/ajpendo.00460.2007"},{"key":"119","doi-asserted-by":"crossref","unstructured":"119 Gasbjerg LS, Bari EJ, Stensen S, Hoe B, Lanng AR, et al. (2021) Dose-dependent efficacy of the glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist GIP(3-30)NH(2) on GIP actions in humans. Diabetes Obes Metab 23: 68\u201374.","DOI":"10.1111\/dom.14186"},{"key":"120","doi-asserted-by":"crossref","unstructured":"120 Asmar M, Asmar A, Simonsen L, Gasbjerg LS, Sparre-Ulrich AH, et al. (2017) The gluco- and liporegulatory and vasodilatory effects of glucose-dependent insulinotropic polypeptide (GIP) are abolished by an antagonist of the human GIP receptor. Diabetes 66: 2363\u20132371.","DOI":"10.2337\/db17-0480"},{"key":"121","doi-asserted-by":"crossref","unstructured":"121 Nakamura T, Tanimoto H, Mizuno Y, Okamoto M, Takeuchi M, et al. (2018) Gastric inhibitory polypeptide receptor antagonist, SKL-14959, suppressed body weight gain on diet-induced obesity mice. Obes Sci Pract 4: 194\u2013203.","DOI":"10.1002\/osp4.164"},{"key":"122","doi-asserted-by":"crossref","unstructured":"122 Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, et al. (1999) Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci U S A 96: 14843\u201314847.","DOI":"10.1073\/pnas.96.26.14843"},{"key":"123","doi-asserted-by":"crossref","unstructured":"123 V\u00e9niant MM, Lu SC, Atangan L, Komorowski R, Stanislaus S, et al. (2024) A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab 6: 290\u2013303.","DOI":"10.1038\/s42255-023-00966-w"},{"key":"124","doi-asserted-by":"crossref","unstructured":"124 Kim SJ, Nian C, Karunakaran S, Clee SM, Isales CM, et al. (2012) GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis. PLoS One 7: e40156.","DOI":"10.1371\/journal.pone.0040156"},{"key":"125","doi-asserted-by":"crossref","unstructured":"125 O\u2019Harte FP, Gault VA, Parker JC, Harriott P, Mooney MH, et al. (2002) Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia 45: 1281\u20131291.","DOI":"10.1007\/s00125-002-0894-6"},{"key":"126","doi-asserted-by":"crossref","unstructured":"126 Gault VA, Flatt PR, Bailey CJ, Harriott P, Greer B, et al. (2002) Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes. Biochem J 367: 913\u2013920.","DOI":"10.1042\/bj20020319"},{"key":"127","doi-asserted-by":"crossref","unstructured":"127 Gault VA, Flatt PR, Harriott P, Mooney MH, Bailey CJ, et al. (2003) Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide. J Endocrinol 176: 133\u2013141.","DOI":"10.1677\/joe.0.1760133"},{"key":"128","doi-asserted-by":"publisher","unstructured":"128 Hinke SA, Gelling RW, Pederson RA, Manhart S, Nian C, et al. (2002) Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes 51: 652\u2013661.","DOI":"10.2337\/diabetes.51.3.652"},{"key":"129","doi-asserted-by":"crossref","unstructured":"129 Knop FK, Urva S, Rettiganti M, Benson CT, Roell WC, et al. (2024) A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy. Diabetes Obes Metab 26: 5474\u20135478.","DOI":"10.1111\/dom.15875"},{"key":"130","doi-asserted-by":"crossref","unstructured":"130 Finan B, Ma T, Ottaway N, M\u00fcller TD, Habegger KM, et al. (2013) Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med 5: 209ra151.","DOI":"10.1126\/scitranslmed.3007218"},{"key":"131","doi-asserted-by":"crossref","unstructured":"131 Frias JP, Bastyr EJ 3rd, Vignati L, Tsch\u00f6p MH, Schmitt C, et al. (2017) The sustained effects of a dual GIP\/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metab 26: 343\u2013352.e342.","DOI":"10.1016\/j.cmet.2017.07.011"},{"key":"132","doi-asserted-by":"crossref","unstructured":"132 Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, et al. (2018) LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab 18: 3\u201314.","DOI":"10.1016\/j.molmet.2018.09.009"},{"key":"133","doi-asserted-by":"crossref","unstructured":"133 Rosenstock J, Wysham C, Fr\u00edas JP, Kaneko S, Lee CJ, et al. (2021) Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. <i>Lancet<\/i> 398: 143\u2013155.","DOI":"10.1016\/S0140-6736(21)01324-6"},{"key":"134","doi-asserted-by":"crossref","unstructured":"134 Fr\u00edas JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, et al. (2021) Tirzepatide <i>versus<\/i> semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 385: 503\u2013515.","DOI":"10.1056\/NEJMoa2107519"},{"key":"135","doi-asserted-by":"publisher","unstructured":"135 Ludvik B, Giorgino F, J\u00f3dar E, Frias JP, Fern\u00e1ndez Land\u00f3 L, et al. (2021) Once-weekly tirzepatide <i>versus<\/i> once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet 398: 583\u2013598.","DOI":"10.1016\/S0140-6736(21)01443-4"},{"key":"136","doi-asserted-by":"crossref","unstructured":"136 Battelino T, Bergenstal RM, Rodr\u00edguez A, Fern\u00e1ndez Land\u00f3 L, Bray R, et al. (2022) Efficacy of once-weekly tirzepatide <i>versus<\/i> once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 10: 407\u2013417.","DOI":"10.1016\/S2213-8587(22)00077-8"},{"key":"137","doi-asserted-by":"crossref","unstructured":"137 Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, et al. (2021) Tirzepatide <i>versus<\/i> insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 398: 1811\u20131824.","DOI":"10.1016\/S0140-6736(21)02188-7"},{"key":"138","doi-asserted-by":"crossref","unstructured":"138 Dahl D, Onishi Y, Norwood P, Huh R, Bray R, et al. (2022) Effect of subcutaneous tirzepatide <i>vs.<\/i> placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA 327: 534\u2013545.","DOI":"10.1001\/jama.2022.0078"},{"key":"139","doi-asserted-by":"crossref","unstructured":"139 Rosenstock J, Fr\u00edas JP, Rodbard HW, Tof\u00e9 S, Sears E, et al. (2023) Tirzepatide <i>vs.<\/i> insulin lispro added to basal insulin in type 2 diabetes: the SURPASS-6 randomized clinical trial. JAMA 330: 1631\u20131640.","DOI":"10.1001\/jama.2023.20294"},{"key":"140","doi-asserted-by":"crossref","unstructured":"140 Inagaki N, Takeuchi M, Oura T, Imaoka T, Seino Y (2022) Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol 10: 623\u2013633.","DOI":"10.1016\/S2213-8587(22)00188-7"},{"key":"141","doi-asserted-by":"crossref","unstructured":"141 Kadowaki T, Chin R, Ozeki A, Imaoka T, Ogawa Y (2022) Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol 10: 634\u2013644.","DOI":"10.1016\/S2213-8587(22)00187-5"},{"key":"142","doi-asserted-by":"crossref","unstructured":"142 Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, et al. (2022) Tirzepatide once weekly for the treatment of obesity. N Engl J Med 387: 205\u2013216.","DOI":"10.1056\/NEJMoa2206038"},{"key":"143","doi-asserted-by":"crossref","unstructured":"143 Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, et al. (2023) Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med 29: 2909\u20132918.","DOI":"10.1038\/s41591-023-02597-w"},{"key":"144","doi-asserted-by":"crossref","unstructured":"144 Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, et al. (2023) Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 402: 613\u2013626.","DOI":"10.1016\/S0140-6736(23)01200-X"},{"key":"145","doi-asserted-by":"crossref","unstructured":"145 Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, et al. (2024) Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med 391: 1193\u20131205.","DOI":"10.1056\/NEJMoa2404881"},{"key":"146","doi-asserted-by":"crossref","unstructured":"146 Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, et al. (2024) Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med 391: 299\u2013310.","DOI":"10.1056\/NEJMoa2401943"},{"key":"147","doi-asserted-by":"crossref","unstructured":"147 Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, et al. (2025) Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 392: 427\u2013437.","DOI":"10.1056\/NEJMoa2410027"},{"key":"148","doi-asserted-by":"crossref","unstructured":"148 Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, et al. (2023) Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 402: 529\u2013544.","DOI":"10.1016\/S0140-6736(23)01053-X"},{"key":"149","doi-asserted-by":"crossref","unstructured":"149 Jastreboff AM, Kaplan LM, Fr\u00edas JP, Wu Q, Du Y, et al. (2023) Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med 389: 514\u2013526.","DOI":"10.1056\/NEJMoa2301972"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/7\/72_EJ25-0087\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T03:32:57Z","timestamp":1751686377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/7\/72_EJ25-0087\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":149,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej25-0087","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"EJ25-0087"}}